ABT vs SYK — Key Metrics

Metric ABT (ABBOTT LABORATORIES) SYK (STRYKER CORP)
Price104.48318.15
Market Cap180.95 Billion121.12 Billion
P/E (TTM)38.8433.63
P/B (Quarterly)3.8754.737
P/S (TTM)3.754.61
Net Profit Margin (TTM)9.713.8
Gross Margin (TTM)56.965.3
ROE (TTM)9.015.6
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

ABBOTT LABORATORIES
vs
 
STRYKER CORP
 
ABBOTT LABORATORIES
vs
 
STRYKER CORP
Performance Comparison
AI Model Recommendation
ABT · ABBOTT LABORATORIES

Underperform

-42
UnderperformOutperform
SYK · STRYKER CORP

Greatly Underperform

-64
UnderperformOutperform
Recommendation Summary

Stock ABT is projected to underperform the market, stock SYK is projected to greatly underperform the market. Upfront Recommendation: ABT.

Financial Metrics
Prices delayed ~15 min
ABT Metrics SYK
$104.48 Price $318.15
— Market Capitalization —
38.84 Price to Earnings Ratio 33.63
3.75 Price to Sales 4.61
26.78 Price to FCF Ratio 26.49
6.59 Price to Gross Profit 7.05
54.6 Price to R&D 72.05
7.7 Price to Current Assets 8.54

ABT vs SYK at a glance

Abbott Laboratories (ABT) and Stryker Corp (SYK) are both Medical Devices companies in the Healthcare sector. ABT is the larger, at $181.0 billion in market value against $121.1 billion for SYK, about 1.5 times the size.

On trailing-twelve-month figures, ABT trades at 38.8 times trailing earnings and SYK at 33.6; net profit margins are 9.7% and 13.8%.

The Upfront Investment model currently rates ABT Underperform and SYK Greatly Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.